Oxidative stress induces p53-dependent apoptosis in hepatoblastoma cell through its nuclear translocation

Genes to Cells

Volumn 12, Issue 4, 2007, Pages 461-471

  Yamamoto, Hideki ^a,b   Ozaki, Toshinori ^a   Nakanishi, Mitsuru ^a   Kikuchi, Hironobu ^a   Yoshida, Kaori ^a   Horie, Hiroshi ^c   Kuwano, Hiroyuki ^b   Nakagawara, Akira ^a  

^a CHIBA CANCER CENTER   (Japan)

^b GUNMA UNIVERSITY   (Japan)

^c CHIBA CHILDREN'S HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; NICOTINAMIDE; PROTEIN P53; PROTEIN PARC; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL FRACTIONATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOPLASM; HEPATOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LIVER CARCINOGENESIS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSACTIVATION; WESTERN BLOTTING; WILD TYPE;

ACTIVE TRANSPORT, CELL NUCLEUS; APOPTOSIS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL NUCLEUS; CHILD; CYTOPLASM; HEPATOBLASTOMA; HUMANS; HYDROGEN PEROXIDE; IN SITU NICK-END LABELING; NIACINAMIDE; OXIDANTS; OXIDATIVE STRESS; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53; VITAMIN B COMPLEX;

EID: 33947622196     PISSN: 13569597     EISSN: 13652443     Source Type: Journal    
DOI: 10.1111/j.1365-2443.2007.01065.x     Document Type: Article

References (46)

1. Aberle, H., Bauer, A., Stappert, J., Kispert, A. & Kemler, R. (1997) β-catenin is a target for the ubiquitin-proteasome pathway. EMBO J. 16, 3797-3804.
2. Aden, D.P., Fogel, A., Plotkin, S., Damjanov, I. & Knowles, B.B. (1979) Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature 282, 615-616.
3. Bosari, S., Viale, G., Roncalli, M., Graziani, D., Borsani, G., Lee, A.K. & Coggi, G. (1995) p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. Am. J. Pathol. 147, 790-798.
4. Bressac, B., Galvin, K.M., Liang, J., Isselbacher, K.J., Wands, J.R. & Ozturk, M. (1990) Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proc. Natl. Acad. Sci. USA 87, 1973-1977.
5. Brooks, C.L. & Gu, W. (2003) Ubiquitination, phosphorylation and acetylation: The molecular basis for p53 regulation. Curr. Opin. Cell Biol. 15, 164-171.
6. Chen, T.C., Hsieh, L.L. & Kuo, T.T. (1995) Absence of p53 gene mutation and infrequent overexpression of p53 protein in hepatoblastoma. J. Pathol. 176, 243-247.
7. Chen, J., Marechal, V. & Levine, A.J. (1993) Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol. 13, 4107-4114.
8. Doi, I. (1976) Establishment of a cell line and its clonal sublines from a patient with hepatoblastoma. Gann 67, 1-10.
9. Dornan, D., Wertz, I., Shimizu, H., Arnott, D., Frantz, G.D., Dowd, P., O'Rourke, K., Koeppen, H. & Dixit, V.M. (2004) The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 429, 86-92.
10. Fritsche, M., Haessler, C. & Brandner, G. (1993) Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 8, 307-318.
11. Gu, W. & Roeder, R.G. (1997) Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90, 595-606.
12. Harada, N., Miyoshi, H., Murai, N., Oshima, H., Tamai, Y., Oshima, M. & Taketo, M.M. (2002) Lack of tumorigenesis in the mouse liver after adenovirus-mediated expression of a dominant stable mutant of β-catenin. Cancer Res. 62, 1971-1977.
13. Harada, N., Oshima, H., Katoh, M., Tamai, Y., Oshima, M. & Taketo, M.M. (2004) Hepatocarcinogenesis in mice with β-catenin and Ha-ras gene mutations. Cancer Res. 64, 48-54.
14. Haupt, Y., Maya, R., Kazaz, A. & Oren, M. (1997) Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299.
15. Henderson, B.R. & Fagotto, F. (2002) The ins and outs of APC and β-catenin nuclear transport. EMBO Rep. 3, 834-839.
16. Hollstein, M., Sidransky, D., Vogelstein, B. & Harris, C.C. (1991) p53 mutations in human cancers. Science 253, 49-53.
17. Honda, R., Tanaka, H. & Yasuda, H. (1997) Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420, 25-27.
18. Hsu, I.C., Tokiwa, T., Bennett, W., Metcalf, R.A., Welsh, J.A., Sun, T. & Harris, C.C. (1993) p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis 14, 987-992.
19. Hughes, L.J. & Michels, V.V. (1992) Risk of hepatoblastoma in familial adenomatous polyposis. Am. J. Med. Genet. 43, 1023-1025.
20. Kawaguchi, Y., Ito, A., Appella, E. & Yao, T.P. (2006) Charge modification at multiple C-terminal lysine residues regulates p53 oligomerization and its nucleus-cytoplasm trafficking. J. Biol. Chem. 281, 1394-1400.
21. Koch, A., Denkhaus, D., Albrecht, S., Leuschner, I., von Schweinitz, D. & Pietsch, T. (1999) Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the β-catenin gene. Cancer Res. 59, 269-273.
22. Kubbutat, M.H., Jones, S.N. & Vousden, K.H. (1997) Regulation of p53 stability by Mdm2. Nature 387, 299-303.
23. Kusafuka, T., Fukuzawa, M., Oue, T., Komoto, Y., Yoneda, A. & Okada, A. (1997) Mutation analysis of p53 gene in childhood malignant solid tumors. J. Pediatr. Surg. 32, 1175-1180.
24. Leng, R.P., Lin, Y., Ma, W., Wu, H., Lemmers, B., Chung, S., Parant, J.M., Lozano, G., Hakem, R. & Benchimol, S. (2003) Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112, 779-791.
25. Llovet, J.M., Burroughs, A. & Bruix, J. (2003) Hepatocellular carcinoma. Lancet 362, 1907-1917.
26. Lluis, J.M., Morales, A., Biasco, C., Colell, A., Mari, M., Garcia-Ruiz, C. & Fernandez-Checa, J.C. (2005) Critical role of mitochondrial glutathione in the survival of hepatocytes during hypoxia. J. Biol. Chem. 280, 3224-3232.
27. Michishita, E., Park, J.Y., Burneskis, J.M., Barrett, J.C. & Horikawa, I. (2005) Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol. Biol. Cell 16, 4623-4635.
28. Moll, U.M., LaQuaglia, M., Benard, J. & Riou, G. (1995) Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc. Natl. Acad. Sci. USA 92, 4407-4411.
29. Moll, U.M., Riou, G. & Levine, A.J. (1992) Two distinct mechanisms alter p53 in breast cancer: Mutation and nuclear exclusion. Proc. Natl. Acad. Sci. USA 89, 7262-7266.
30. Nagase, H. & Nakamura, Y. (1993) Mutations of the APC (adenomatous polyposis coli) gene. Hum. Mutat. 2, 425-434.
31. Nikolaev, A.Y., Li, M., Puskas, N., Qin, J. & Gu, W. (2003) Parc: A cytoplasmic anchor for p53. Cell 112, 29-40.
32. +-dependent tubulin deacetylase. Mol. Cell 11, 437-444.
33. Ogryzko, V.V., Schiltz, R.L., Russanova, V., Howard, B.H. & Nakatani, Y. (1996) The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 29, 953-959.
34. Ohnishi, H., Kawamura, M., Hanada, R., Kaneko, Y., Tsunoda, Y., Hongo, T., Bessho, F., Yokomori, K. & Hayashi, Y. (1996) Infrequent mutations of the TP53 gene and no amplification of the MDM2 gene in hepatoblastomas. Genes Chromosomes Cancer 15, 187-190.
35. Ostermeyer, A.G., Runko, E., Winkfield, B., Ahn, B. & Moll, U.M. (1996) Cytoplasmically sequestered wild-type p53 protein in neuroblastoma is relocated to the nucleus by a C-terminal peptide. Proc. Natl. Acad. Sci. USA 93, 15190-15194.
36. Prives, C. & Hall, P.A. (1999) The p53 pathway. J. Pathol. 187, 112-126.
37. de Ruijter, A.J., van Gennip, A.H., Caron, H.N., Kemp, S. & van Kuilenburg, A.B. (2003) Histone deacetylases (HDACs): Characterization of the classical HDAC family. Biochem. J. 370, 737-749.
38. Shieh, S.Y., Ikeda, M., Taya, Y. & Prives, C. (1997) DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91, 325-334.
39. Sionov, R.V. & Haupt, Y. (1999) The cellular response to p53: The decision between life and death. Oncogene 18, 6145-6157.
40. Stommel, J.M., Marchenko, N.D., Jimenez, G.S., Moll, U.M., Hope, T.J. & Wahl, G.M. (1999) A leucine-rich nuclear export signal in the p53 tetramerization domain: Regulation of subcellular localization and p53 activity by NES masking. EMBO J. 18, 1660-1672.
41. Takayasu, H., Horie, H., Hiyama, E., Matsunaga, T., Hayashi, Y., Watanabe, Y., Suita, S., Kaneko, M., Sasaki, F., Hashizume, K., Ozaki, T., Furuuchi, K., Tada, M., Ohnuma, N. & Nakagawara, A. (2001) Frequent deletions and mutations of the β-catenin gene are associated with overexpression of cyclin D1 and fibronectin and poorly differentiated histology in childhood hepatoblastoma. Clin. Cancer Res. 7, 901-908.
42. Vogan, K., Berstein, M., Leclerc, J.M., Brisson, L., Brossard, J., Brodeur, G.M., Pelletier, J. & Gros, P. (1993) Absence of p53 gene mutations in primary neuroblastomas. Cancer Res. 53, 5269-5273.
43. Vogelstein, B., Lane, D. & Levine, A.J. (2000) Surfing the p53 network. Nature 408, 307-310.
44. Vousden, K.H. & Lu, X. (2002) Live or let die: The cell's response to p53. Nat. Rev. Cancer 2, 594-604.
45. Watcharasit, P., Bijur, G.N., Song, L., Zhu, J., Chen, X. & Jope, R.S. (2003) Glycogen synthase kinase-3β (GSK3β) binds to and promotes the actions of p53. J. Biol. Chem. 278, 48872-48879.
46. Watcharasit, P., Bijur, G.N., Zmijewski, J.W., Song, L., Zmijewska, A., Chen, X., Johnson, G.V. & Jope, R.S. (2002) Direct, activating interaction between glycogen synthase kinase-3β and p53 after DNA damage. Proc. Natl. Acad. Sci. USA 99, 7951-7955.